Developing life-changing therapies for complex neurological disorders with axonal dysfunction
Toward a Cure for neuromuscular and neurodegenerative disorders
We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral nerve disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.
We are developing novel therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential applications in other complex neurological disorders.
We currently have multiple programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in regulatory preclinical development; our second program focusing on brain penetrant and selective HDAC6i is currently in lead optimization.
Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.
The company is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and in the collaboration between the VIB labs of Joris de Wit and Bart De Strooper.
Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.